Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage Glioblastoma This is a trial for recurrent glioblastoma patients who have failed Temodar and Avastin. There is another trial of Val-083 for newly diagnosed MGMT unmethylated patients. Val-083 is a chemotherapy similar to Temodar but works at a different location on the DNA of the tumor cells. It should theoretically not be affected by the MGMT status and may work even when the tumor is resistant to Temodar
